Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety
Identifieur interne : 000F74 ( Main/Exploration ); précédent : 000F73; suivant : 000F75Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety
Auteurs : Ewa Wi Sik-Szewczyk [Pologne] ; Magdalena Romanowska [Pologne] ; Paweł Mielnik [Pologne] ; Hanna Chwali Ska-Sadowska [Pologne] ; Lidia B. Brydak [Pologne] ; Marzena Olesi Ska [Pologne] ; Jakub Z Bek [Pologne]Source :
- Clinical Rheumatology [ 0770-3198 ] ; 2010-06-01.
English descriptors
Abstract
Abstract: The objective of this study is to evaluate efficacy and safety of influenza vaccine in systemic lupus erythematosus (SLE) patients. We studied SLE patients and healthy subjects immunised with inactivated influenza vaccine. Efficacy was measured by comparing humoral response to vaccine antigens between groups. Safety was monitored by SLEDAI and serological markers. Subjects attended visits at baseline and on post-vaccination weeks 4 and 12. We enrolled 62 SLE patients and 47 healthy subjects. In post-immunisation week 4, anti-haemagglutinin antibody titres rose in the patient group at least 6.23-fold, compared to 11.90-fold among controls (P ≤ 0.05). The seroconversion rate range was 53-56% among patients and 72-85% among controls (P < 0.05 for strains H1N1 and H3N2, NS for strain type B). The seroprotection rate ranged between 62% and 73% and between 90% and 98% in the patient and control group, respectively (P < 0.05). In post-vaccination week 12, the antibody titre was higher at least 3.86-fold in the patient group and 7.65-fold among controls. The seroconversion rate range was 32-40% among patients and 64-70% among controls, while the seroprotection rate ranged between 43% and 50% and between 79% and 94%, respectively (P < 0.005 for three strains). We identified one severe and six mild to moderate SLE exacerbations by week 12. The anti-nuclear antibodies and anti-double-stranded DNA titres grew by post-immunisation week 4 (P < 0.05). The post-vaccination response was weaker in SLE patients compared to healthy subjects. Immunisation did not change underlying disease activity.
Url:
DOI: 10.1007/s10067-010-1373-y
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001221
- to stream Istex, to step Curation: 001221
- to stream Istex, to step Checkpoint: 000241
- to stream Main, to step Merge: 000F82
- to stream Main, to step Curation: 000F74
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety</title><author><name sortKey="Wi Sik Szewczyk, Ewa" sort="Wi Sik Szewczyk, Ewa" uniqKey="Wi Sik Szewczyk E" first="Ewa" last="Wi Sik-Szewczyk">Ewa Wi Sik-Szewczyk</name></author><author><name sortKey="Romanowska, Magdalena" sort="Romanowska, Magdalena" uniqKey="Romanowska M" first="Magdalena" last="Romanowska">Magdalena Romanowska</name></author><author><name sortKey="Mielnik, Pawel" sort="Mielnik, Pawel" uniqKey="Mielnik P" first="Paweł" last="Mielnik">Paweł Mielnik</name></author><author><name sortKey="Chwali Ska Sadowska, Hanna" sort="Chwali Ska Sadowska, Hanna" uniqKey="Chwali Ska Sadowska H" first="Hanna" last="Chwali Ska-Sadowska">Hanna Chwali Ska-Sadowska</name></author><author><name sortKey="Brydak, Lidia B" sort="Brydak, Lidia B" uniqKey="Brydak L" first="Lidia B." last="Brydak">Lidia B. Brydak</name></author><author><name sortKey="Olesi Ska, Marzena" sort="Olesi Ska, Marzena" uniqKey="Olesi Ska M" first="Marzena" last="Olesi Ska">Marzena Olesi Ska</name></author><author><name sortKey="Z Bek, Jakub" sort="Z Bek, Jakub" uniqKey="Z Bek J" first="Jakub" last="Z Bek">Jakub Z Bek</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1041971C4FEB9CD06B2A3612E04E92D8BD2C455F</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1007/s10067-010-1373-y</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-GHPFLTH2-4/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001221</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001221</idno><idno type="wicri:Area/Istex/Curation">001221</idno><idno type="wicri:Area/Istex/Checkpoint">000241</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000241</idno><idno type="wicri:doubleKey">0770-3198:2010:Wi Sik Szewczyk E:anti:influenza:vaccination</idno><idno type="wicri:Area/Main/Merge">000F82</idno><idno type="wicri:Area/Main/Curation">000F74</idno><idno type="wicri:Area/Main/Exploration">000F74</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety</title><author><name sortKey="Wi Sik Szewczyk, Ewa" sort="Wi Sik Szewczyk, Ewa" uniqKey="Wi Sik Szewczyk E" first="Ewa" last="Wi Sik-Szewczyk">Ewa Wi Sik-Szewczyk</name><affiliation wicri:level="1"><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation><affiliation></affiliation></author><author><name sortKey="Romanowska, Magdalena" sort="Romanowska, Magdalena" uniqKey="Romanowska M" first="Magdalena" last="Romanowska">Magdalena Romanowska</name><affiliation wicri:level="1"><country xml:lang="fr">Pologne</country><wicri:regionArea>National Influenza Center, National Institute of Public Health, National Institute of Hygiene, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Mielnik, Pawel" sort="Mielnik, Pawel" uniqKey="Mielnik P" first="Paweł" last="Mielnik">Paweł Mielnik</name><affiliation wicri:level="1"><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Chwali Ska Sadowska, Hanna" sort="Chwali Ska Sadowska, Hanna" uniqKey="Chwali Ska Sadowska H" first="Hanna" last="Chwali Ska-Sadowska">Hanna Chwali Ska-Sadowska</name><affiliation wicri:level="1"><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Brydak, Lidia B" sort="Brydak, Lidia B" uniqKey="Brydak L" first="Lidia B." last="Brydak">Lidia B. Brydak</name><affiliation wicri:level="1"><country xml:lang="fr">Pologne</country><wicri:regionArea>National Influenza Center, National Institute of Public Health, National Institute of Hygiene, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Olesi Ska, Marzena" sort="Olesi Ska, Marzena" uniqKey="Olesi Ska M" first="Marzena" last="Olesi Ska">Marzena Olesi Ska</name><affiliation wicri:level="1"><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02-637, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Z Bek, Jakub" sort="Z Bek, Jakub" uniqKey="Z Bek J" first="Jakub" last="Z Bek">Jakub Z Bek</name><affiliation wicri:level="1"><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Microbiology and Serology, Institute of Rheumatology, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Clinical Rheumatology</title><title level="j" type="sub">Journal of the International League of Associations for Rheumatology</title><title level="j" type="abbrev">Clin Rheumatol</title><idno type="ISSN">0770-3198</idno><idno type="eISSN">1434-9949</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>London</pubPlace><date type="published" when="2010-06-01">2010-06-01</date><biblScope unit="volume">29</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="605">605</biblScope><biblScope unit="page" to="613">613</biblScope></imprint><idno type="ISSN">0770-3198</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0770-3198</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Humoral response</term><term>Influenza vaccination</term><term>Lupus erythematosus</term><term>Safety</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: The objective of this study is to evaluate efficacy and safety of influenza vaccine in systemic lupus erythematosus (SLE) patients. We studied SLE patients and healthy subjects immunised with inactivated influenza vaccine. Efficacy was measured by comparing humoral response to vaccine antigens between groups. Safety was monitored by SLEDAI and serological markers. Subjects attended visits at baseline and on post-vaccination weeks 4 and 12. We enrolled 62 SLE patients and 47 healthy subjects. In post-immunisation week 4, anti-haemagglutinin antibody titres rose in the patient group at least 6.23-fold, compared to 11.90-fold among controls (P ≤ 0.05). The seroconversion rate range was 53-56% among patients and 72-85% among controls (P < 0.05 for strains H1N1 and H3N2, NS for strain type B). The seroprotection rate ranged between 62% and 73% and between 90% and 98% in the patient and control group, respectively (P < 0.05). In post-vaccination week 12, the antibody titre was higher at least 3.86-fold in the patient group and 7.65-fold among controls. The seroconversion rate range was 32-40% among patients and 64-70% among controls, while the seroprotection rate ranged between 43% and 50% and between 79% and 94%, respectively (P < 0.005 for three strains). We identified one severe and six mild to moderate SLE exacerbations by week 12. The anti-nuclear antibodies and anti-double-stranded DNA titres grew by post-immunisation week 4 (P < 0.05). The post-vaccination response was weaker in SLE patients compared to healthy subjects. Immunisation did not change underlying disease activity.</div></front></TEI><affiliations><list><country><li>Pologne</li></country></list><tree><country name="Pologne"><noRegion><name sortKey="Wi Sik Szewczyk, Ewa" sort="Wi Sik Szewczyk, Ewa" uniqKey="Wi Sik Szewczyk E" first="Ewa" last="Wi Sik-Szewczyk">Ewa Wi Sik-Szewczyk</name></noRegion><name sortKey="Brydak, Lidia B" sort="Brydak, Lidia B" uniqKey="Brydak L" first="Lidia B." last="Brydak">Lidia B. Brydak</name><name sortKey="Chwali Ska Sadowska, Hanna" sort="Chwali Ska Sadowska, Hanna" uniqKey="Chwali Ska Sadowska H" first="Hanna" last="Chwali Ska-Sadowska">Hanna Chwali Ska-Sadowska</name><name sortKey="Mielnik, Pawel" sort="Mielnik, Pawel" uniqKey="Mielnik P" first="Paweł" last="Mielnik">Paweł Mielnik</name><name sortKey="Olesi Ska, Marzena" sort="Olesi Ska, Marzena" uniqKey="Olesi Ska M" first="Marzena" last="Olesi Ska">Marzena Olesi Ska</name><name sortKey="Romanowska, Magdalena" sort="Romanowska, Magdalena" uniqKey="Romanowska M" first="Magdalena" last="Romanowska">Magdalena Romanowska</name><name sortKey="Z Bek, Jakub" sort="Z Bek, Jakub" uniqKey="Z Bek J" first="Jakub" last="Z Bek">Jakub Z Bek</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F74 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F74 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:1041971C4FEB9CD06B2A3612E04E92D8BD2C455F
|texte= Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety
}}
| This area was generated with Dilib version V0.6.33. |  |